Use of a small molecule integrin activator as a systemically administered vaccine adjuvant in controlling Chagas disease

Use of a small molecule integrin activator as a systemically administered vaccine adjuvant in controlling Chagas disease

Abstract The development of suitable safe adjuvants to enhance appropriate antigen-driven immune responses remains a challenge. Here we describe the adjuvant properties of a small molecule activator of the integrins αLβ2 and α4β1, named 7HP349, which can be safely delivered systemically independent...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Nandadeva Lokugamage, Imran H. Chowdhury, Ronald J. Biediger, Robert V. Market, Sayadeth Khounlo, Navin D. Warier, Shen-An Hwang, Jeffrey K. Actor, Darren G. Woodside, Upendra Marathi, Peter Vanderslice, Nisha Jain Garg
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2021
Materias:
Immunologic diseases. Allergy
RC581-607
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
Acceso en línea:https://doaj.org/article/fa56993f549b4cbda0b8eb8236c01b18
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Internet

https://doaj.org/article/fa56993f549b4cbda0b8eb8236c01b18

Ejemplares similares